Overview Allograft Dysfunction in Heart Transplant Status: Recruiting Trial end date: 2024-04-01 Target enrollment: Participant gender: Summary The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes. Phase: Phase 4 Details Lead Sponsor: Paul KimCollaborator: Astellas Pharma IncTreatments: Regadenoson